GSK shares dip amid rising selling pressure

Traders Union
All News
Financial News
Gsk slides 2.48% today to GBX1923.50

Highlights

GSK exhibits a bullish long-term trend, trading above its major moving averages but faces short-term resistance near recent highs.
Momentum indicators diverge with overbought signals and weak short-term trend strength, while buyer dominance remains positive intraday.
Expected five-day price range is GBX 1,879.00 to GBX 1,990.25 with over 80% probability of an upward move, though downside breaks below support could accelerate selling.

Anton Kharitonov, expert at Traders Union, views GSK’s recent decline to GBX 1,923.50 as a clear signal of ongoing short-term weakness. He highlights that the stock failing to hold its 50-day moving average, combined with mixed momentum signals, suggests persistent bear pressure below surface-level optimism. The lack of recent news flow could amplify volatility and uncertainty for investors here. Kharitonov notes that multiple overbought indicators contradict the bullish trend, raising concerns of a technical pullback. "Despite a strong weekly profile, I remain cautious — traders should prepare for a possible break below GBX 1,879.00 if current selling momentum continues."

Viktoras Karapetjanc, expert at Traders Union, sees GSK’s resilience above its 200-day moving average as confirmation of robust upside structure. He is confident that with most weekly indicators in Buy territory and ongoing intraday buyer dominance, the market offers multiple setups for bullish positioning. Karapetjanc believes the absence of fresh news does not undermine underlying institutional demand. "With the bullish structure intact and an 80% probability of upside, I expect further growth and see potential for a break above the GBX 2,000 level."

Jainam Mehta, market strategist, considers GSK’s price near the day’s lows and recent downside as a tactical opportunity. He notes the divergence between short-term overbought readings and prevailing bullish weekly momentum could set up a contrarian entry. Mehta sees possible range-bound action but remains alert to a breakout in either direction. "If the price reclaims GBX 1,967.82, I would look for a momentum breakout toward GBX 1,990.25."

Short-term overbought signals diverge from broader bullish momentum

GSK is trading just above its 20-day moving average (GBX 1,915.58) and 200-day moving average (GBX 1,863.60), but now below the 50-day moving average (GBX 1,967.82), suggesting the stock maintains a bullish longer-term trend but faces short-term resistance. The nearest dynamic support is the Ichimoku Kijun at GBX 1,907, and resistance is likely at the 50-day moving average or the GBX 2,000 round level.

Momentum signals are mixed: the MACD is neutral on the daily timeframe, while the Average Directional Index (ADX) shows weak trend strength with a short-term "Sell" but a longer-term "Buy" on the weekly chart. The Relative Strength Index (RSI) points to buying pressure, yet the Stochastic RSI and Commodity Channel Index (CCI) both signal overbought conditions. Bull/Bear Power (BBP) remains positive, indicating intraday buyer dominance, and also flags an overbought market. The Awesome Oscillator supports the broader bullish structure. The stock is down GBX 49.00 or 2.48% from the previous close. An upside gap of approximately GBX 3.50 was recorded at the open. The current price is near the day's low, with intraday volatility at 2.30%, suggesting persistent downside pressure after the open. There is a divergence between short-term overbought signals and the underlying bullish momentum profile.

Earlier, analysts noted that GSK was transitioning from a bearish outlook toward renewed upside momentum amid a developing buyer bias. The latest technical signals highlight increasing short-term pressures against a still-bullish long-term trend, making a decisive move above the recent resistance zone a potential catalyst for accelerated gains.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.